Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the optimal safe and tolerable dose of gemcitabine
in combination with once daily or twice daily dose of PTK/ZK in patients with unresectable
pancreatic cancer. The Phase II part of this study planned to determine the antitumor
activity of this regimen and its effectiveness of preventing tumor growth and spread.